Enovix vs XCHG
Enovix reported revenue of $32 million in fiscal 2025, 1.3 times XCHG's $25 million in fiscal 2025. Enovix's revenue grew 37.9% in its latest year, and XCHG's fell 40.5%. Enovix had an operating margin of -557.0%, against -129.9% at XCHG. Their fiscal years end in different months (December 28 and December 31), so the periods don't line up exactly.
Side by side
| Enovix | XCHG | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 28, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $32M | $25M |
| Revenue growth | 37.9% | −40.5% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | 19.2% | 46.2% |
| Operating margin | −557.0% | −129.9% |
| Net margin | −492.6% | −129.5% |
| Free cash flow | −$114M | — |
| Free cash flow margin | −356.7% | — |
| Return on capital | −62.6% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $58M | $0M |
| Change in diluted share count | 11.6% | 117.3% |
| Last close | $1.29 | $3.08 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $16,784 | — |
| Piotroski F-score | 5 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
EnovixXCHG
Operating margin
Percent of revenue
EnovixXCHG
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
EnovixXCHG